{"id":62731,"date":"2026-04-09T20:38:49","date_gmt":"2026-04-09T12:38:49","guid":{"rendered":"https:\/\/flcube.com\/?p=62731"},"modified":"2026-04-09T20:38:50","modified_gmt":"2026-04-09T12:38:50","slug":"genfleet-therapeutics-secures-first-ever-nmpa-breakthrough-designation-for-kras-g12d-inhibitor-in-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62731","title":{"rendered":"GenFleet Therapeutics Secures First\u2011Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer"},"content":{"rendered":"\n<p><strong>GenFleet Therapeutics (Shanghai) Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2595:HKG\">HKG:\u202f2595<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted <strong>Breakthrough Therapy Designation (BTD)<\/strong> to <strong>GFH375<\/strong>, a <strong>KRAS G12D inhibitor<\/strong>, for treating <strong>KRAS G12D\u2011mutant metastatic pancreatic cancer<\/strong> patients who have received <strong>at least one prior systemic therapy<\/strong>. This marks the <strong>first BTD awarded for pancreatic cancer<\/strong> targeting this mutation in China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Breakthrough Therapy Designation (BTD)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>GFH375 (KRAS G12D inhibitor)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>KRAS G12D\u2011mutant metastatic pancreatic cancer (2L+)<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td><strong>First BTD<\/strong> for this indication in China<\/td><\/tr><tr><td><strong>Global Synonym<\/strong><\/td><td>VS\u20117375 (Verastem Oncology)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> <strong>KRAS G12D<\/strong> \u2013 Most common KRAS mutation in pancreatic cancer (~40% of cases)<\/li>\n\n\n\n<li><strong>Binding Mode:<\/strong> <strong>Non\u2011covalent<\/strong> inhibition of KRAS G12D protein<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Blocks interaction with downstream effector proteins, disrupting sustained pathway activation and suppressing tumor cell proliferation<\/li>\n\n\n\n<li><strong>Preclinical Profile:<\/strong><\/li>\n\n\n\n<li>Dose\u2011 and duration\u2011dependent tumor growth inhibition<\/li>\n\n\n\n<li><strong>Low off\u2011target risk<\/strong> in kinase selectivity profiling<\/li>\n\n\n\n<li>Favorable safety target engagement<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-clinical-development\">Global Clinical Development<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Partner<\/th><th>Status<\/th><th>Regulatory Designation<\/th><\/tr><\/thead><tbody><tr><td><strong>China<\/strong><\/td><td>GenFleet (originator)<\/td><td>BTD secured Apr\u202f2026<\/td><td><strong>NMPA Breakthrough Therapy<\/strong><\/td><\/tr><tr><td><strong>United States<\/strong><\/td><td><strong>Verastem Oncology<\/strong><\/td><td>Clinical initiated 2025<\/td><td><strong>FDA Fast\u2011Track<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>GenFleet partnered with <strong>Verastem Oncology<\/strong> for overseas development; US trials commenced under FDA fast\u2011track status in 2025.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pancreatic Cancer Landscape:<\/strong> KRAS G12D mutations drive ~40% of cases; median survival for metastatic patients remains <strong>&lt;12\u202fmonths<\/strong> with existing chemotherapy, creating urgent demand for targeted therapies.<\/li>\n\n\n\n<li><strong>First\u2011Mover Advantage:<\/strong> As the <strong>first KRAS G12D inhibitor<\/strong> to achieve BTD in China, GFH375 positions for <strong>accelerated NMPA review<\/strong> and priority assessment, potentially shaving <strong>12\u201318\u202fmonths<\/strong> off standard approval timelines.<\/li>\n\n\n\n<li><strong>Global KRAS Market:<\/strong> Targeted KRAS inhibitors represent a <strong>US$5\u202fbillion+ addressable market<\/strong>; G12D subset previously considered &#8220;undruggable&#8221; until recent breakthroughs.<\/li>\n\n\n\n<li><strong>Competitive Dynamics:<\/strong> Mirati\/Amgen&#8217;s sotorasib (G12C) validated the class; G12D\u2011specific agents face less competition with larger eligible populations.<\/li>\n\n\n\n<li><strong>Revenue Forecast:<\/strong> Peak China sales potential estimated at <strong>\u00a52.5\u20134\u202fbillion<\/strong> (US$350\u2011550\u202fmillion) assuming 2028\u20112029 launch and 25\u201130% penetration in 2L+ G12D\u2011mutant pancreatic cancer.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory pathways, clinical outcomes, and commercial projections for GFH375. Actual results may differ due to risks including trial failures, approval delays, competitive entry from other KRAS programs, and reimbursement negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040900158_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026040900158_c.\"><\/object><a id=\"wp-block-file--media-afd01416-5c3c-461f-96d3-2dc767646585\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040900158_c.pdf\">2026040900158_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040900158_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-afd01416-5c3c-461f-96d3-2dc767646585\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GenFleet Therapeutics (Shanghai) Inc. (HKG:\u202f2595) announced that China&#8217;s National Medical Products Administration (NMPA) has granted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[34,16,1682,4345],"class_list":["post-62731","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-breakthrough-therapy","tag-cancer","tag-genfleet-therapeutics","tag-hkg-2595"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GenFleet Therapeutics Secures First\u2011Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GenFleet Therapeutics (Shanghai) Inc. (HKG:\u202f2595) announced that China&#039;s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to GFH375, a KRAS G12D inhibitor, for treating KRAS G12D\u2011mutant metastatic pancreatic cancer patients who have received at least one prior systemic therapy. This marks the first BTD awarded for pancreatic cancer targeting this mutation in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62731\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenFleet Therapeutics Secures First\u2011Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer\" \/>\n<meta property=\"og:description\" content=\"GenFleet Therapeutics (Shanghai) Inc. (HKG:\u202f2595) announced that China&#039;s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to GFH375, a KRAS G12D inhibitor, for treating KRAS G12D\u2011mutant metastatic pancreatic cancer patients who have received at least one prior systemic therapy. This marks the first BTD awarded for pancreatic cancer targeting this mutation in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62731\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-09T12:38:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-09T12:38:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62731#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62731\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GenFleet Therapeutics Secures First\u2011Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer\",\"datePublished\":\"2026-04-09T12:38:49+00:00\",\"dateModified\":\"2026-04-09T12:38:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62731\"},\"wordCount\":398,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Breakthrough therapy\",\"Cancer\",\"GenFleet Therapeutics\",\"HKG: 2595\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62731#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62731\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62731\",\"name\":\"GenFleet Therapeutics Secures First\u2011Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-09T12:38:49+00:00\",\"dateModified\":\"2026-04-09T12:38:50+00:00\",\"description\":\"GenFleet Therapeutics (Shanghai) Inc. (HKG:\u202f2595) announced that China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to GFH375, a KRAS G12D inhibitor, for treating KRAS G12D\u2011mutant metastatic pancreatic cancer patients who have received at least one prior systemic therapy. This marks the first BTD awarded for pancreatic cancer targeting this mutation in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62731#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62731\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62731#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenFleet Therapeutics Secures First\u2011Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GenFleet Therapeutics Secures First\u2011Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"GenFleet Therapeutics (Shanghai) Inc. (HKG:\u202f2595) announced that China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to GFH375, a KRAS G12D inhibitor, for treating KRAS G12D\u2011mutant metastatic pancreatic cancer patients who have received at least one prior systemic therapy. This marks the first BTD awarded for pancreatic cancer targeting this mutation in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62731","og_locale":"en_US","og_type":"article","og_title":"GenFleet Therapeutics Secures First\u2011Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer","og_description":"GenFleet Therapeutics (Shanghai) Inc. (HKG:\u202f2595) announced that China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to GFH375, a KRAS G12D inhibitor, for treating KRAS G12D\u2011mutant metastatic pancreatic cancer patients who have received at least one prior systemic therapy. This marks the first BTD awarded for pancreatic cancer targeting this mutation in China.","og_url":"https:\/\/flcube.com\/?p=62731","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-09T12:38:49+00:00","article_modified_time":"2026-04-09T12:38:50+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62731#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62731"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GenFleet Therapeutics Secures First\u2011Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer","datePublished":"2026-04-09T12:38:49+00:00","dateModified":"2026-04-09T12:38:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62731"},"wordCount":398,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Breakthrough therapy","Cancer","GenFleet Therapeutics","HKG: 2595"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62731#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62731","url":"https:\/\/flcube.com\/?p=62731","name":"GenFleet Therapeutics Secures First\u2011Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-09T12:38:49+00:00","dateModified":"2026-04-09T12:38:50+00:00","description":"GenFleet Therapeutics (Shanghai) Inc. (HKG:\u202f2595) announced that China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to GFH375, a KRAS G12D inhibitor, for treating KRAS G12D\u2011mutant metastatic pancreatic cancer patients who have received at least one prior systemic therapy. This marks the first BTD awarded for pancreatic cancer targeting this mutation in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62731#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62731"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62731#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GenFleet Therapeutics Secures First\u2011Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62731"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62731\/revisions"}],"predecessor-version":[{"id":62734,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62731\/revisions\/62734"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}